A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

Background: Pegylated recombinant human arginase (PEG-BCT-100) is an arginine depleting drug. Preclinical studies showed that HCC is reliant on exogenous arginine for growth due to the under-expression of the arginine regenerating enzymes argininosuccinate synthetase (ASS) and ornithine transcarbamy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Stephen L., Cheng, Paul N.M., Liu, Angela M., Chan, Landon L., Li, Leung, Chu, Cheuk M., Chong, Charing C.N., Lau, Yat M., Yeo, Winnie, Ng, Kelvin K.C., Yu, Simon C.H., Mok, Tony S.K., Chan, Anthony W.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426309/
https://www.ncbi.nlm.nih.gov/pubmed/33856599
http://dx.doi.org/10.1007/s10637-021-01111-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426309/
https://www.ncbi.nlm.nih.gov/pubmed/33856599
http://dx.doi.org/10.1007/s10637-021-01111-8

Ejemplares similares